Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response

Ilic, 2016, Epidemiology of pancreatic cancer, World J Gastroenterol, 22, 9694, 10.3748/wjg.v22.i44.9694 Conroy, 2018, FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer, N Engl J Med, 379, 2395, 10.1056/NEJMoa1809775 Suker, 2016, FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis, Lancet Oncol., 17, 801, 10.1016/S1470-2045(16)00172-8 Rose, 2014, Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival, Ann Surg Oncol, 21, 1530, 10.1245/s10434-014-3486-z Vidri, 2019, Better defining the role of total neoadjuvant radiation: changing paradigms in locally advanced pancreatic cancer, Ann Surg Oncol, 26, 3701, 10.1245/s10434-019-07584-5 Versteijne, 2020, Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial, J Clin Oncol : Off J Am Soc Clin Oncol, 10.1200/JCO.19.02274 Tachezy, 2014, Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749), BMC Cancer, 14, 411, 10.1186/1471-2407-14-411 Tran, 2020, Phase 2 trial of neoadjuvant FOLFIRINOX and intensity modulated radiation therapy concurrent with fixed-dose rate-gemcitabine in patients with borderline resectable pancreatic cancer, Int J Radiat Oncol Biol Phys, 106, 124, 10.1016/j.ijrobp.2019.08.057 Polistina, 2014, Neoadjuvant strategies for pancreatic cancer, World J Gastroenterol, 20, 9374 Pietrasz, 2019, How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An AGEO-French multicentric cohort, Ann Surg Oncol, 26, 109, 10.1245/s10434-018-6931-6 Murphy, 2019, Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial, JAMA Oncol, 5, 1020, 10.1001/jamaoncol.2019.0892 Auclin, 2021, Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort, Br J Cancer, 124, 1941, 10.1038/s41416-021-01341-w Kurahara, 2019, Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study, Langenbeck's Arch Surg, 404, 167, 10.1007/s00423-019-01754-5 Peng, 2019, Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer, Hepatobiliary Pancreat Dis Int : HBPD INT, 18, 373, 10.1016/j.hbpd.2019.05.007 Kourie, 2019, Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: an AGEO multicentric retrospective cohort, Clin Res Hepatol Gastroenterol, 43, 663, 10.1016/j.clinre.2019.03.007 He, 2018, Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer?, Ann Surg, 268, 1, 10.1097/SLA.0000000000002672 Boffa, 2017, Using the national cancer database for outcomes research: a review, JAMA Oncol, 3, 1722, 10.1001/jamaoncol.2016.6905 Schulz, 2015, NeoFLOT: multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors, Int J Cancer, 137, 678, 10.1002/ijc.29403 Park, 2013, A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma, Cancer Chemother Pharmacol, 72, 815, 10.1007/s00280-013-2257-z Ludmir, 2017, Total neoadjuvant therapy for rectal cancer: an emerging option, Cancer, 123, 1497, 10.1002/cncr.30600 Kim, 2018, Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE), BMC Cancer, 18, 538, 10.1186/s12885-018-4466-7 Oneda, 2019, Are we sure that adjuvant chemotherapy is the best approach for resectable pancreatic cancer? Are we in the era of neoadjuvant treatment? A review of current literature, J Clin Med, 8 Parmar, 2014, Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma, Surgery, 156, 280, 10.1016/j.surg.2014.03.001 Russ, 2010, Impact of selection bias on the utilization of adjuvant therapy for pancreas adenocarcinoma, Ann Surg Oncol, 17, 371, 10.1245/s10434-009-0759-z Casciani, 2018, Pancreatic cancer in the era of neoadjuvant therapy: a narrative overview, Chirurgia, 113, 307, 10.21614/chirurgia.113.3.307 Khattab, 2019, Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma, J Gastrointest Oncol, 10, 918, 10.21037/jgo.2019.07.02 Hashemi-Sadraei, 2018, Clinical characteristics of patients experiencing pathologic complete response following neoadjuvant therapy for borderline resectable/locally advanced pancreatic adenocarcinoma, Am J Clin Oncol, 41, 982, 10.1097/COC.0000000000000409 Li, 2016, Wait-and-see treatment strategies for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis, Oncotarget, 7, 44857, 10.18632/oncotarget.8622 Truty, 2019, Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer, Ann Surg Rombouts, 2016, Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer, Ann Surg Oncol, 23, 4352, 10.1245/s10434-016-5373-2 Goel, 2018, The utility of preoperative vascular grading in patients undergoing surgery first for pancreatic cancer: does radiologic arterial or venous involvement predict pathologic margin status?, J Oncol, 2018, 7675262 Roland, 2015, The addition of postoperative chemotherapy is associated with improved survival in patients with pancreatic cancer treated with preoperative therapy, Ann Surg Oncol, 22, S1221, 10.1245/s10434-015-4854-z Katz, 2016, JAMA Surg, 151, 10.1001/jamasurg.2016.1137 Katz, 2017, Alliance for clinical trials on oncology, BMC Cancer, 17, 505, 10.1186/s12885-017-3441-z Bradley, 2019, Upfront surgery versus neoadjuvant therapy for resectable pancreatic cancer: systematic review and bayesian Network meta-analysis, Sci Rep, 9, 4354, 10.1038/s41598-019-40951-6 Cady, 1997, Basic principles in surgical oncology, Arch Surg, 132, 338, 10.1001/archsurg.1997.01430280012001 Datta, 2021, A call for caution in overinterpreting exceptional outcomes after radical surgery for pancreatic cancer, Ann Surg, 274, e82, 10.1097/SLA.0000000000004471 Valle, 2014, Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study, J Clin Oncol, 32, 504, 10.1200/JCO.2013.50.7657